,
Ahmed, Fayyaz
Gaul, Charly
García-Moncó, Juan Carlos
Sommer, Katherine
Martelletti, Paolo
Funding for this research was provided by:
Allergan plc (Not applicable)
Article History
Received: 16 October 2018
Accepted: 20 February 2019
First Online: 7 March 2019
Ethics approval and consent to participate
: Before study initiation, all investigators obtained ethical approval from their respective ethics committee.The study was conducted in accordance with the International Council on Harmonisation Guideline for Good Clinical Practice.Informed consent was obtained from each patient before enrolment.
: Not applicable.
: Fayyaz Ahmed declares that he has received honorarium for consultancy and lecturing from Allergan, Eneura, ElectroCore, and Novartis, which is paid to the British Association for the Study of Headache and the Migraine Trust. Charly Gaul is the director of the Migraine and Headache Clinic Königstein. He has received honoraria from Allergan, Ratiopharm, Boehringer Ingelheim, Lilly, Novartis, Desitin Arzneimittel, Cerbotec, Bayer Vital, Hormosan, ElectroCore und Grünenthal, Reckitt Benckiser, and Teva. Dr. Gaul has no ownership interests and does not own any pharmaceutical company stocks. Juan Carlos García-Moncó declares he has consulted for Allergan. Katherine Sommer is an employee of Allergan plc (Marlow, Buckinghamshire, UK) and holds stock in the company. Paolo Martelletti declares that he has received research funds or advisory board honoraria from Allergan, Amgen, ElectroCore, Elytra Pharma, Teva, Novartis, and Bayer; travel reimbursement from Springer Nature and EMA; and royalties from Springer.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.